Recent Company News

• 02:55 AM ET Sep 09, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:09 AM ET Sep 09, 2026
  

  UCB's CIMZIA receives FDA Breakthrough Therapy designation for antiphospholipid syndrome (APS) in pregnant women (€206.90, 0.00)

• 09:11 AM ET Sep 01, 2026
  

  Oil & Gas, Health Care and Chemicals lead; Autos & Parts and Travel & Leisure lag:

• 08:33 AM ET Sep 01, 2026
  

  StreetAccount Themes Headlines (1-Sep)

• 05:26 PM ET Aug 31, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 03:29 PM ET Aug 31, 2026
  

  White House confirms 9 new MFN agreements with drug manufacturers including midsized biotech

• 10:42 AM ET Aug 05, 2026
  

  Epilepsia Open publishes results of post hoc data analysis of FINTEPLA (fenfluramine) in patients with Lennox-Gastaut syndrome (€230.10, +6.80)

• 04:14 AM ET Aug 03, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:06 AM ET Aug 03, 2026
  

  UCB upgraded to hold from underperform at Jefferies (€222.90, 0.00)

• 09:00 AM ET Jul 30, 2026
  

  Transcript Intelligence: UCB Q2 Earnings Guidance